Related Experiment Videos
Drugging cell cycle kinases in cancer therapy
1Centre for Cancer Therapeutics, Institute for Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, England. jdebono@icr.ac.uk
Current Drug Targets
|April 29, 2005
Summary
New cancer therapies target cell cycle kinases like cyclin-dependent kinases (Cdks). While existing drugs show promise, newer, more specific inhibitors are in development to reduce toxicity and improve anti-cancer efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cell cycle kinases, including cyclin-dependent kinases (Cdks), are crucial for cell division.
- Aberrant expression of these kinases is common in various cancers, making them attractive therapeutic targets.
- Current Cdk inhibitors demonstrate anticancer activity but often exhibit significant toxicity due to off-target effects.
Purpose of the Study:
- To review the role of cell cycle kinases in cancer.
- To discuss the development of novel Cdk inhibitors with improved specificity.
- To highlight emerging therapeutic strategies targeting both Cdk and non-Cdk cell cycle kinases.
Main Methods:
- Review of preclinical and clinical data on existing and novel cell cycle kinase inhibitors.
- Analysis of drug mechanisms of action and toxicity profiles.
- Discussion of ongoing clinical trials for new anticancer agents.
Main Results:
- Several Cdk inhibitors have shown preclinical and clinical anticancer activity.
- Existing inhibitors often lack specificity, leading to dose-limiting toxicities.
- Newer generations of inhibitors are being developed for enhanced target specificity and reduced side effects.
Conclusions:
- Targeting cell cycle kinases remains a promising strategy for cancer therapy.
- Development of specific inhibitors for Cdks and non-Cdk kinases is crucial for improving therapeutic outcomes.
- Next-generation kinase inhibitors represent a hopeful advancement in anticancer drug development.